Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 2, 2013, Pages 317-323

  Verhoven, Bret ^a   Yan, Yan ^b   Ritter, Mark ^a   Khor, Li Yan ^c   Hammond, Elizabeth ^d   Jones, Christopher ^e   Amin, Mahul ^f   Bahary, Jean Paul ^g   Zeitzer, Kenneth ^h   Pollack, Alan ⁱ  

^a UNIVERSITY OF WISCONSIN   (United States)

^b RTOG Statistical Center   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d LDS HOSPITAL   (United States)

^e Radiological Associates of Sacramento Medical Group Inc   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^h ALBERT EINSTEIN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION; CORRELATIVE ANALYSIS; IMMUNOHISTOCHEMISTRY; INDEPENDENT PREDICTORS; METHODS AND MATERIALS; MULTIVARIABLE ANALYSIS; PROPORTIONAL HAZARDS; RADIATION THERAPY ONCOLOGY GROUPS;

ONCOLOGY; PATHOLOGY; PATIENT MONITORING; PESTICIDE EFFECTS; RADIOTHERAPY; TISSUE;

DISEASES;

GONADORELIN AGONIST; KI 67 ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CONTROL; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; STAINING;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL PROLIFERATION; FLUTAMIDE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84877585402     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.01.016     Document Type: Article

References (19)

1. M. Roach 3rd, F. Waldman, and A. Pollack Predictive models in external beam radiotherapy for clinically localized prostate cancer Cancer 115 2009 3112 3120
2. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
3. L.Y. Khor, K. Bae, and A. Pollack COX-2 expression predicts prostate-cancer outcome: Analysis of data from the RTOG 92-02 trial Lancet Oncol 8 2007 912 920
4. L.Y. Khor, J. Moughan, and T. Al-Saleem Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on Radiation Therapy Oncology Group protocol 92-02 Clin Cancer Res 13 2007 3585 3590
5. R. Li, K. Heydon, and M.E. Hammond Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in Radiation Therapy Oncology Group protocol 86-10 Clin Cancer Res 10 2004 4118 4124
6. A.A. Keshgegian, E. Johnston, and A. Cnaan Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma Am J Clin Pathol 110 1998 443 449
7. T.J. Sebo, J.C. Cheville, and D.L. Riehle Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer Am J Surg Pathol 26 2002 431 439
8. D. Cowen, P. Troncoso, and V.S. Khoo Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy Clin Cancer Res 8 2002 1148 1154
9. A. Pollack, M. DeSilvio, and L.Y. Khor Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02 J Clin Oncol 22 2004 2133 2140
10. D.M. Berney, A. Gopalan, and S. Kudahetti Ki-67 and outcome in clinically localised prostate cancer: Analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study Br J Cancer 100 2009 888 893
11. M. Borre, S.M. Bentzen, and B. Nerstrom Tumor cell proliferation and survival in patients with prostate cancer followed expectantly J Urol 159 1998 1609 1614
12. J. Gerdes, H. Lemke, and H. Baisch Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67 J Immunol 133 1984 1710 1715
13. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
14. D.R. Cox Regression models and life-tables J R Stat Soc Series B Stat Methodol 34 1972 187 220
15. R.J. Gray A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154
16. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
17. S.B. Edge, D.R. Byrd, and C.C. Compton AJCC Cancer Staging Manual 7th ed. 2010 Springer New York
18. D. Vallbohmer, H.E. Marcus, and S.E. Baldus Comparative analysis of four histopathological classification systems to discriminate benign and malignant behaviour in gastrointestinal stromal tumors Anticancer Res 28 2008 367 372
19. A. Pollack, D. Cowen, and P. Troncoso Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x Cancer 97 2003 1630 1638